BACKGROUND
Thyroid hormone plays a major role in brain development of the baby during pregnancy. During the 1st trimester, all the thyroid hormone that the baby gets comes from the mother. After that, the baby’s thyroid starts working, but the baby still needs some thyroid hormone from the mother. Hypothyroidism is common in women who are pregnant or are planning pregnancy. While overt hypothyroidism (high TSH and low FT4) clearly requires treatment with levothyroxine, it is less clear that subclinical hypothyroidism (High TSH, normal FT4) needs to be treated. Because some studies have associated hypothyroidism in the mother with miscarriage, preterm birth, and impaired brain development in the baby, doctors have traditionally had a low threshold for starting levothyroxine treatment. However, the evidence has changed substantially since the 2017 American Thyroid Association (ATA) guidelines. Trials of treatment for subclinical hypothyroidism have highlighted the importance of timing during pregnancy and the possibility of overtreatment. Further, trials treating pregnant women with normal thyroid levels but positive TPO antibodies have generally failed to show any benefit.
The 2026 ATA guidelines represent a meaningful shift from reflex treatment toward confirming persistent hypothyroidism and individualized decision-making. The key aspects in the section on hypothyroidism have been outlined here.
THE FULL ARTICLE TITLE
Korevaar TIM, et al. American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid 2026;36(5):481–544; doi: 10.1177/10507256261445624. PMID: 42219800.
SUMMARY OF THE STUDY
The 2026 ATA guidelines on hypothyroidism in pregnancy outlines recommendations depending on the timing (prior to pregnancy or during pregnancy) and the degree of hypothyroidism (subclinical or over hypothyroidism).
In individuals with subclinical hypothyroidism, it is suggested that TPO antibody status is not required to guide the decision to treat. Levothyroxine therapy may be considered for persistent subclinical hypothyroidism prior to pregnancy or during the first trimester of pregnancy.